Ms. Cheung has 20 years of financial and general management experience at emerging growth life science companies. She joins Oculis from the NASDAQ-listed company Anika Therapeutics, Inc. where she was CFO from 2013 to 2020. During her tenure, she played a vital role in redefining and executing the company’s mission, vision and long-range financial-operational targets; supported and enabled U.S. launches of key therapeutics products; and executed on three strategic acquisitions. Prior to Anika, Ms. Cheung held a series of financial management positions of increasing responsibility at Transkaryotic Therapies, Inc., which was acquired by Shire Pharmaceuticals in 2005. Ms. Cheung began her career in the technology audit practice at PricewaterhouseCoopers. She holds a Bachelor of Business Administration degree in Accounting from the University of Massachusetts in Amherst, an MBA from Boston University, and was certified as CPA in Massachusetts.
Dr. Dehmel brings to Oculis close to 20 years of global experience in early and late-phase drug development, clinical operations, biostatistics, regulatory and medical affairs across multiple therapeutic areas. He joins Oculis from OxThera where he was Chief Medical Officer since 2017 and where he was responsible for drug development, clinical program and medical affairs while supporting early development and research collaborations.
Prior to OxThera, he held roles of increasing responsibilities mainly at Amgen where he spent more than 10 years of his career but also with companies such as Novo Nordisk and GSK. His last role at Amgen saw him as Executive Medical Director, Global Development Leader Calcimimetic franchise. In this role, he was responsible for the global clinical development for the first-in-class calcimimetic Sensipar®/Mimpara® and the approval of Parsabiv®.
Dr. Dehmel gained his Doctor of Medicine degree from Free University Berlin – Medical School and his clinical training in Internal Medicine at Charité University in Berlin, Germany.
Mr. Ding has more than 25 years of experience in general management, successful go-to-market strategies, business development and licensing, and operational excellence across multiple healthcare segments. He joins Oculis from Fresenius-Kabi, where he served as Country President for China, building market leadership and a strong competitive portfolio. Prior to Fresenius-Kabi, Mr. Ding spent more than 10 years with Novartis in China in leadership roles of increasing responsibility. Mr. Ding was also a member of the Global Executive Committee of Novartis Vaccines. Prior to Novartis, Mr. Ding held various senior commercial roles at major pharmaceutical companies in China including Bristol Myers Squibb and Xi’an Janssen (a Johnson & Johnson company). Mr. Ding gained his Bachelor of Science in biochemistry from Wuhan University and completed an EMBA at the China Europe International Business School.